Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Gluz

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine ResistanceSophie Mueller, Isabel Grote, Stephan Bartels, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerNadia Harbeck, Matthias W Beckmann, Achim Rody, et al.
Anticancer Research|March 16, 2016
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German StudyAndreas Schneeweiss, Frank Förster, Hans Tesch, et al.
Breast Cancer (Tokyo, Japan)|September 3, 2022
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studiesYutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|July 19, 2019
Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer PatientsMattea Reinisch, Oleg Gluz, Beyhan Ataseven, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 16, 2022
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancerIsabel Grote, Stephan Bartels, Henriette Christgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapyOleg Gluz, Karin Mengele, Manfred Schmitt, et al.
Breast Cancer Research and Treatment|February 15, 2011
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trialOleg Gluz, Peter Wild, Cornelia Liedtke, et al.
Breast Care (Basel, Switzerland)|May 20, 2021
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute ExperienceOliver Stoetzer, Dorit Di Gioia, Rolf Dieter Issels, et al.
International Journal of Cancer|June 19, 2008
Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensityOleg Gluz, Peter Wild, Robert Meiler, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine ResistanceSophie Mueller, Isabel Grote, Stephan Bartels, et al.
Breast Care (Basel, Switzerland)|April 10, 2014
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerNadia Harbeck, Matthias W Beckmann, Achim Rody, et al.
Anticancer Research|March 16, 2016
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German StudyAndreas Schneeweiss, Frank Förster, Hans Tesch, et al.
Breast Cancer (Tokyo, Japan)|September 3, 2022
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studiesYutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|July 19, 2019
Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer PatientsMattea Reinisch, Oleg Gluz, Beyhan Ataseven, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 16, 2022
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancerIsabel Grote, Stephan Bartels, Henriette Christgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapyOleg Gluz, Karin Mengele, Manfred Schmitt, et al.
Breast Cancer Research and Treatment|February 15, 2011
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trialOleg Gluz, Peter Wild, Cornelia Liedtke, et al.
Breast Care (Basel, Switzerland)|May 20, 2021
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute ExperienceOliver Stoetzer, Dorit Di Gioia, Rolf Dieter Issels, et al.
International Journal of Cancer|June 19, 2008
Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensityOleg Gluz, Peter Wild, Robert Meiler, et al.
Pageof 10